Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that the incidence of infection with methicillin-resistant Staphylococcus aureus (MRSA) has been increasing since the late 1980's, resulting in high morbidity, mortality, and cost. According to a new Pharmacor study entitled Methicillin-Resistant Staphylococcus aureus, new agents that have launched over the past several years have expanded clinicians' therapeutic options against MRSA, but experts indicate that all of the currently marketed antibiotics have drawbacks.

"There is a clear need in the market for therapeutic alternatives to currently marketed agents for treating MRSA," said Aarti Raja, Ph.D., analyst at Decision Resources. "Vancomycin (Eli Lilly's Vancocin, generics) and linezolid (Pfizer's Zyvox/Zyvoxid) are the current drugs of choice, but these products have important limitations. Zyvox/Zyvoxid is expensive and has side effects, including myelosuppression, while vancomycin offers suboptimal activity against staphylococci and a problematic side effect profile."

New therapeutic approaches to MRSA infections include monoclonal antibodies, which may be useful in treating immunocompromised individuals suffering life-threatening infection. Because they will be used in combination with antibiotics, they will have an additive effect on the MRSA drug market.

About Methicillin-Resistant Staphylococcus aureus

Antibiotic resistance in the hospital setting has risen dramatically over the past 10-15 years and is a major source of concern for clinicians. MRSA is one of the most common antibiotic-resistant pathogens in hospitals, and it is a formidable pathogen to treat because it is resistant to most classes of antibiotics.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

   For more information, contact:     Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,

Spiriva will Attain Sales of Approximately $2.8 Billion for Treatment of Chronic Obstructive Pulmonary Disease (COPD) in 2013

View Now